

**Remarks**

Claims 28-54 were pending. Claims 28-54 were subject to a seven (7) way Restriction Requirement.

Claims 28-54 have been cancelled and replaced with new claims 55-62 to more clearly recite the present invention. Claims 55-62 are directed to substantially the same subject matter as former claims 28-54. Support for this amendment is apparent. Thus, no new matter is added.


**Election/Restriction**

Applicants hereby elect to prosecute Group I drawn to a polypeptide. This election is made without traverse. While the election of Group I is without traverse, Applicants reserve the right to traverse restriction requirements between the other asserted claim groups.

**Closing Remarks**


• Entry of the Response and Amendment and allowance of the pending claims are respectfully requested.

Respectfully submitted,



Teresa O. Bittenbender  
Registration No. 47,425  
Attorney for Applicant

DECHERT  
1717 Arch Street  
4000 Bell Atlantic Tower  
Philadelphia, PA 19103-2789  
Fax: (215) 994-2222  
Attn: Teresa O. Bittenbender, Esq.  
(215-994-2213)



Claims following entry of amendment mailed October 14, 2002

55. An isolated polypeptide comprising a member selected from the group consisting

of

- (a) an amino acid sequence matching SEQ ID NO:2 or SEQ ID NO:4;
- (b) an immunogenic polypeptide comprising a fragment sequence of at least 15 amino acids that matches an aligned contiguous segment of SEQ ID NO:2 or SEQ ID NO:4;

wherein the isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell immune response to a polypeptide having the sequence of SEQ ID NO:2 or SEQ ID NO:4;

56. The isolated polypeptide of claim 55, wherein the polypeptide is according to (a).

57. The isolated polypeptide of claim 55, wherein the polypeptide is according to (b).


58. The isolated polypeptide of claim 55, wherein the immunogenic fragment of (b) comprises at least 20 amino acids.

59. The isolated polypeptide of claim 55, wherein the isolated polypeptide consists of SEQ ID NO:2 or SEQ ID NO:4.

60. A fusion protein comprising the isolated polypeptide of Claim 55.

61. An immunogenic composition comprising the polypeptide of Claim 55 and a pharmaceutically acceptable carrier.

62. The immunogenic composition of Claim 61, wherein the vaccine comprises at least one other *Moraxella catarrhalis* antigen.



RECEIVED

OCT 28 2002

TECH CENTER 1600/2900

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Application Number 09/857,669

Filing Date September 21, 2001

First Named Inventor Ruelle, Jean-Louis

Group Art Unit 1645

Examiner Name Baskar, P.

Total Number of Pages in This Submission

Attorney Docket Number BM45339

**ENCLOSURES (check all that apply)**☐ Fee Transmittal Form☐ Fee Attached☒ Amendment / Reply☐ After Final☐ Affidavits/declaration(s)☐ Extension of Time Request☐ Express Abandonment Request☐ Information Disclosure Statement☐ Certified Copy of Priority Document(s)☐ Response to Missing Parts/  
Incomplete Application☐ Response to Missing Parts  
under 37 CFR 1.52 or 1.53☐ Assignment Papers  
(for an Application)☐ Drawing(s)☐ Licensing-related Papers☐ Petition☐ Petition to Convert to a  
Provisional Application☐ Power of Attorney, Revocation  
Change of Correspondence  
Address☐ Terminal Disclaimer☐ Request for Refund☐ CD, Number of CD(s) \_\_\_\_\_☐ After Allowance Communication  
to Group☐ Appeal Communication to Board  
of Appeals and Interferences☐ Appeal Communication to Group  
(Appeal Notice, Brief, Reply Brief)☐ Proprietary Information☐ Status Letter☒ Other Enclosure(s) (please  
identify below):

Acknowledgment Postcard

Remarks

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**Firm  
or  
Individual name

Teresa O. Bittenbender, Reg. #47,425

Signature

Date

October 14, 2002

**CERTIFICATE OF MAILING**I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: October 14, 2002

Typed or printed name

Teresa O. Bittenbender

Signature

Date

October 14, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.